Joseph Schultz, MD
Urology · Mobile, ALNPI 1821073800
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 93.9% of the total across 292 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 36 manufacturers, the largest accounting for just 18.3% — the pattern of someone who eats at a lot of different presentations.
Across 292 payments — averaging $19.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$1K
- Astellas Pharma US Inc$734
- Dendreon Pharmaceuticals LLC$677
- Sumitomo Pharma America, Inc.$581
- Pfizer$328
- Endo Pharmaceuticals Inc.$252
- plus $2K from 30 others
Across 1 payment — averaging $7000.00 each. An ownership or investment interest held by the physician or an immediate family member.
- Cornerstone Urology Network, LLC$7K
What the payments were for
- Food & beverage$5,47094%
- Education$3536%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson(3 entities) | 60 | $1,067 |
| Astellas Pharma US Inc | 35 | $734 |
| Dendreon Pharmaceuticals LLC | 22 | $677 |
| Sumitomo Pharma America, Inc. | 32 | $581 |
| Pfizer | 19 | $328 |
| Endo Pharmaceuticals Inc. | 13 | $252 |
| Urogen Pharma, Inc. | 13 | $247 |
| Coloplast | 12 | $244 |
| Endo USA, Inc. | 9 | $216 |
| Myovant Sciences Inc. | 16 | $212 |
| Myriad Genetic Laboratories, Inc. | 7 | $125 |
| AbbVie(2 entities) | 6 | $125 |
| Procept Biorobotics Corporation | 3 | $117 |
| Urovant Sciences Inc | 5 | $84 |
| Bayer | 4 | $75 |
| Olympus America Inc. | 2 | $61 |
| Boston Scientific | 3 | $59 |
| Progenics Pharmaceuticals, Inc. | 3 | $55 |
| Novartis | 3 | $55 |
| 180 Medical, Inc. | 2 | $54 |
| C. R. Bard, Inc. & Subsidiaries | 2 | $50 |
| Accord Healthcare, Inc. | 3 | $49 |
| Teleflex LLC | 2 | $45 |
| Baxter Healthcare | 2 | $41 |
| Tolmar, Inc. | 2 | $37 |
| Ferring Pharmaceuticals Inc. | 2 | $28 |
| Convatec Inc. | 1 | $25 |
| Blue Earth Diagnostics | 1 | $25 |
| Immunitybio, Inc. | 1 | $25 |
| Antares Pharma, Inc. | 1 | $25 |
| Hollister Incorporated | 1 | $22 |
| Rochester Medical Corporation | 1 | $21 |
| Verity Pharmaceuticals Inc. | 1 | $19 |
| Mission Pharmacal Company | 1 | $17 |
| Telix Pharmaceuticals | 1 | $16 |
| ABC Home Medical Supply, Inc. | 1 | $12 |
How this compares
$5,823 in reported general payments places this provider in the 70th percentile of 179 urology providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ErleadaApalutamide | 159 | $2,250,558 |
| XtandiEnzalutamide | 79 | $1,106,737 |
| OrgovyxRelugolix | 208 | $551,917 |
| Abiraterone Acetate | 70 | $175,934 |
| MyrbetriqMirabegron | 108 | $59,409 |
| GemtesaVibegron | 96 | $58,998 |
| Tamsulosin Hcl | 797 | $11,014 |
| Finasteride | 716 | $8,734 |
| Potassium Citrate ErPotassium Citrate | 50 | $4,670 |
| Methenamine Hippurate | 47 | $3,683 |
| Testosterone Cypionate | 55 | $1,837 |
| Solifenacin Succinate | 38 | $1,437 |
| Trospium Chloride | 12 | $1,378 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 48 | $1,271 |
| Trospium Chloride ErTrospium Chloride | 14 | $1,226 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonErleada | $1,067 | $2,250,558159 claims |
| Astellas Pharma US IncXtandi, Myrbetriq | $734 | $1,166,146187 claims |
| Sumitomo Pharma America, Inc.Orgovyx, Gemtesa | $581 | $610,915304 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 179 urology providers in Alabama.
Other urology in Mobile
- Lorie FleckMobile$26K
- Zachary ReardonMobile$19K
- Ted KleinMobile$18K
- Austin YoungerMobile$18K
- William BlaylockMobile$13K
- Guy OswaltMobile$9K
- Kristie Blanchard-BurchMobile$8K
- Paul ScottMobile$8K
- William SandersonMobile$7K
- Robert HelmMobile$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.